Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
A phase 3 trial of Enfortumab vedotin, Cisplatin, Mitomycin C, Gemcitabine and Pembrolizumab in bladder & urothelial cancer, run by Astellas Pharma Global Development, Inc., now recruiting.
Overview
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) is a phase 3 interventional study registered as NCT07566156 by Astellas Pharma Global Development, Inc., with 390 participants planned, started 2026-05-11 and due to reach its primary completion in 2030-03-31. Interventions recorded: Enfortumab vedotin, Conventional Radiotherapy, Hypofractionated Radiotherapy, Cisplatin, Fluorouracil and Mitomycin C.
Similar pages
not linked directly; found by shared links- TrialA Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Shares Astellas, Enfortumab vedotin, Pfizer (incl. Seagen), Bladder & urothelial cancer and the tag pipeline.
- TrialEfficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
Shares Mitomycin C, Gemcitabine, Cisplatin, Bladder & urothelial cancer and the tag pipeline.
- TrialSymbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Shares Astellas, Enfortumab vedotin, Pfizer (incl. Seagen), Bladder & urothelial cancer and the tag pipeline.
- TrialModular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
Shares Enfortumab vedotin, Gemcitabine, Cisplatin, Bladder & urothelial cancer and the tag pipeline.
- TrialA Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Shares Astellas, Enfortumab vedotin, Pfizer (incl. Seagen), Pembrolizumab and the tag pipeline.
- TrialA Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Shares Astellas, Enfortumab vedotin, Pembrolizumab and the tag pipeline.
- TrialA Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
Shares Mitomycin C, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
Shares Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.